Treatment of diseases like diabetes, cancer, multiple sclerosis or neurodegenerative diseases such as Alzheimer's still poses a tremendous challenge to modern medicine. Nanomedicine, meaning the use of nanotechnology in therapy and diagnostics, may offer promising solutions.
At the EuroNanoMedicine 2009 conference, leading experts from various disciplines such as medicine, nanotechnology, chemistry, cell biology and toxicology will present and discuss recent progress and results. The conference will take place on September 28-30, 2009 in Bled, Slovenia.
The programme will cover current topics such as targeted nanomedicine and therapeutic concepts, overcoming biological barriers, medical diagnostics and sensor devices as well as biocompatibility and toxicity of nanomaterials for medical applications. In addition to scientific issues, political and societal aspects of nanomedicine in Europe will also be adressed.
Nanomaterials are usually known from industrial applications, for example functional surface coatings. In nanomedicine, nanoparticles may be used as drug carriers, protecting the drug against degradation or enhancing uptake by the body. Surface modification of the nano transporters by introducing certain biological functionalities aims at targeted delivery, delivering the drug to the site where it is needed. This can enhance the efficiency of drug intake and decrease potential side effects.
The EuroNanoMedicine 2009 is organized by the multidisciplinary integrated project NanoBioPharmaceutics together with the projects NanoEar and MediTrans. All three projects are funded by the European Commission. Within NanoBioPharmaceutics, 25 partners including 12 university departments, six research institutes, four SMEs and three large pharmaceutical companies from 12 EU countries and the state of Israel are cooperating closely. The project is running for four years and will end in September 2010.
NanoBioPharmaceutics is aiming at the development of biodegradable nanoparticle based carrier systems to transport protein or peptide drugs safely across physiological barriers and release them at the target site within the body. For example, a drug for the treatment of Alzheimer's disease has to pass the blood brain barrier which protects the brain from unwanted or harmful substances. For diabetes patients oral intake of insulin instead of injections would mean a tremendous increase of quality of life. Additionally, NanoBioPharmaceutics investigates new cell culture test systems to compare the results with those obtained from animal testing. A long term goal is to find methods for the reduction and maybe eventually the replacement of animal experiments which are currently required for testing new medication.
At the end of the third project year, a broad range of nanocarrier systems has been designed within NanoBioPharmaceutics. These are currently being optimized and investigated for their suitability to transport drugs via oral or nasal uptake or across the blood brain barrier.Contact:
Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology
16.08.2017 | BIAS - Bremer Institut für angewandte Strahltechnik GmbH
Sustainability is the business model of tomorrow
04.08.2017 | Technische Universität Chemnitz
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
17.08.2017 | Physics and Astronomy
17.08.2017 | Earth Sciences
17.08.2017 | Physics and Astronomy